ESTABLISHING IMMUNE TOLERANCE IN ISLET CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES (T1D)
Up to a total of $900,000 for up to three years. - Wednesday January 07, 2026 (LOI)
Breakthrough T1D, USThis funding opportunity aims to support the development of tolerance induction approaches for islet cell therapy that enables graft-specific immune protection without compromising natural immune defenses.
